+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Uveitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 147 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5913360
Uveitis, a significant cause of blindness in the United States, is experiencing an increasing prevalence. This has led to substantial growth prospects for the global uveitis treatment market. The market has shown consistent expansion, with projections indicating strong growth during the forecast period of 2024 to 2031.

North America and Europe Lead in Clinical Trials

Clinical trials for uveitis treatment are actively underway in North America and Europe. The United Kingdom and France are at the forefront of clinical research in Europe, while countries such as India, Singapore, South Korea, and China are gaining momentum due to the high prevalence of uveitis among their populations.

North America: The Largest Regional Market

North America currently dominates the global uveitis treatment market, representing more than 30% of the total market. It is expected to maintain its leading position, expanding at a CAGR of 7.3% over the forecast period. By the end of 2024, the North American market is projected to exceed US$270 million, offering substantial opportunities for investors.

The United States is poised to drive revenue growth in the North American uveitis treatment market, with market revenue expected to grow 1.8 times by the end of 2024 compared to 2016.

Canada is also set to make significant contributions to the market's expansion, with projections indicating a market valuation in excess of US$50 million by 2024, growing at a CAGR of 6.3% during the forecast period.

APAC Region Emerges as a Lucrative Market

The Asia-Pacific (APAC) region is expected to see impressive growth in the uveitis treatment market, expanding at a CAGR of 6.7% and nearing a market valuation of US$194 million by 2024. Japan is the largest market within APAC, representing more than 25% of the total market and expected to expand at a CAGR of 6.8% over the forecast period.

China stands out as the fastest-growing market in the region, projected to exceed US$40 million over the forecast period. Meanwhile, revenue from the Indian market is anticipated to grow 1.7 times by 2024.

Innovations in Uveitis Treatment

The uveitis treatment market is witnessing substantial innovation, with leading market players enhancing their product portfolios by introducing new drugs. Notably, DE-109 (phase III), manufactured by Santen Pharmaceutical Co. Ltd. (sirolimus), is in the pipeline for uveitis treatment and has received orphan drug designation from U.S. and European regulatory authorities for treating non-infectious posterior uveitis.

However, the manufacturing of sterile formulations poses significant challenges, leading companies to align with Good Manufacturing Practices (GMP) and regulatory guidelines to ensure product quality.

The global uveitis treatment market is set for exciting growth opportunities, with North America and the APAC regions emerging as the most attractive regions for investors. As new therapies continue to develop, the market is expected to address the growing prevalence of uveitis and improve the quality of life for affected individuals.

Global Uveitis Treatment Market: Segmentation

By Treatment Type

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

By Disease Type

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

By Cause

  • Infectious Uveitis
  • Non-infectious Uveitis

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Uveitis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Uveitis Treatment Market Outlook, 2018 - 2031
3.1. Global Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Corticosteroids
3.1.1.2. Immunosuppressant
3.1.1.3. Monoclonal Antibodies
3.1.1.4. Cycloplegic Agents
3.1.1.5. Antibiotics
3.1.1.6. Antivirals
3.1.1.7. Antifungal
3.1.1.8. Analgesics
3.2. Global Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Anterior Uveitis Treatment
3.2.1.2. Posterior Uveitis Treatment
3.2.1.3. Intermediate Uveitis Treatment
3.2.1.4. PanUveitis Treatment
3.3. Global Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Infectious Uveitis Treatment
3.3.1.2. Non-infectious Uveitis Treatment
3.4. Global Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.4.1.3. Online Pharmacies
3.4.1.4. Drug Stores
3.5. Global Uveitis Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Uveitis Treatment Market Outlook, 2018 - 2031
4.1. North America Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Corticosteroids
4.1.1.2. Immunosuppressant
4.1.1.3. Monoclonal Antibodies
4.1.1.4. Cycloplegic Agents
4.1.1.5. Antibiotics
4.1.1.6. Antivirals
4.1.1.7. Antifungal
4.1.1.8. Analgesics
4.2. North America Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Anterior Uveitis Treatment
4.2.1.2. Posterior Uveitis Treatment
4.2.1.3. Intermediate Uveitis Treatment
4.2.1.4. PanUveitis Treatment
4.3. North America Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Infectious Uveitis Treatment
4.3.1.2. Non-infectious Uveitis Treatment
4.4. North America Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.1.3. Online Pharmacies
4.4.1.4. Drug Stores
4.5. North America Uveitis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.5.1.2. U.S. Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.5.1.3. U.S. Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
4.5.1.4. U.S. Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1.5. Canada Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.5.1.6. Canada Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.5.1.7. Canada Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
4.5.1.8. Canada Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Uveitis Treatment Market Outlook, 2018 - 2031
5.1. Europe Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Corticosteroids
5.1.1.2. Immunosuppressant
5.1.1.3. Monoclonal Antibodies
5.1.1.4. Cycloplegic Agents
5.1.1.5. Antibiotics
5.1.1.6. Antivirals
5.1.1.7. Antifungal
5.1.1.8. Analgesics
5.2. Europe Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Anterior Uveitis Treatment
5.2.1.2. Posterior Uveitis Treatment
5.2.1.3. Intermediate Uveitis Treatment
5.2.1.4. PanUveitis Treatment
5.3. Europe Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Infectious Uveitis Treatment
5.3.1.2. Non-infectious Uveitis Treatment
5.4. Europe Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. Online Pharmacies
5.4.1.4. Drug Stores
5.5. Europe Uveitis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.2. Germany Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.3. Germany Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.4. Germany Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.5. U.K. Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.6. U.K. Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.7. U.K. Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.8. U.K. Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.9. France Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.10. France Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.11. France Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.12. France Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.13. Italy Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.14. Italy Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.15. Italy Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.16. Italy Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.17. Turkey Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.18. Turkey Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.19. Turkey Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.20. Turkey Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.21. Russia Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.22. Russia Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.23. Russia Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.24. Russia Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.25. Rest of Europe Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.26. Rest of Europe Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.27. Rest of Europe Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
5.5.1.28. Rest of Europe Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Uveitis Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Corticosteroids
6.1.1.2. Immunosuppressant
6.1.1.3. Monoclonal Antibodies
6.1.1.4. Cycloplegic Agents
6.1.1.5. Antibiotics
6.1.1.6. Antivirals
6.1.1.7. Antifungal
6.1.1.8. Analgesics
6.2. Asia Pacific Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Anterior Uveitis Treatment
6.2.1.2. Posterior Uveitis Treatment
6.2.1.3. Intermediate Uveitis Treatment
6.2.1.4. PanUveitis Treatment
6.3. Asia Pacific Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Infectious Uveitis Treatment
6.3.1.2. Non-infectious Uveitis Treatment
6.4. Asia Pacific Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. Online Pharmacies
6.4.1.4. Drug Stores
6.5. Asia Pacific Uveitis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.2. China Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.3. China Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.4. China Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.5. Japan Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.6. Japan Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.7. Japan Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.8. Japan Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.9. South Korea Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.10. South Korea Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.11. South Korea Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.12. South Korea Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.13. India Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.14. India Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.15. India Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.16. India Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.17. Southeast Asia Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.18. Southeast Asia Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.19. Southeast Asia Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.20. Southeast Asia Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Uveitis Treatment Market Outlook, 2018 - 2031
7.1. Latin America Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Corticosteroids
7.1.1.2. Immunosuppressant
7.1.1.3. Monoclonal Antibodies
7.1.1.4. Cycloplegic Agents
7.1.1.5. Antibiotics
7.1.1.6. Antivirals
7.1.1.7. Antifungal
7.1.1.8. Analgesics
7.2. Latin America Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Anterior Uveitis Treatment
7.2.1.2. Posterior Uveitis Treatment
7.2.1.3. Intermediate Uveitis Treatment
7.2.1.4. PanUveitis Treatment
7.3. Latin America Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Infectious Uveitis Treatment
7.3.1.2. Non-infectious Uveitis Treatment
7.4. Latin America Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. Online Pharmacies
7.4.1.4. Drug Stores
7.5. Latin America Uveitis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.2. Brazil Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.3. Brazil Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
7.5.1.4. Brazil Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.5. Mexico Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.6. Mexico Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.7. Mexico Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
7.5.1.8. Mexico Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.9. Argentina Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.10. Argentina Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.11. Argentina Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
7.5.1.12. Argentina Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.13. Rest of Latin America Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.14. Rest of Latin America Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.15. Rest of Latin America Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
7.5.1.16. Rest of Latin America Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Uveitis Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Uveitis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Corticosteroids
8.1.1.2. Immunosuppressant
8.1.1.3. Monoclonal Antibodies
8.1.1.4. Cycloplegic Agents
8.1.1.5. Antibiotics
8.1.1.6. Antivirals
8.1.1.7. Antifungal
8.1.1.8. Analgesics
8.2. Middle East & Africa Uveitis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Anterior Uveitis Treatment
8.2.1.2. Posterior Uveitis Treatment
8.2.1.3. Intermediate Uveitis Treatment
8.2.1.4. PanUveitis Treatment
8.3. Middle East & Africa Uveitis Treatment Market Outlook, by Cause, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Infectious Uveitis Treatment
8.3.1.2. Non-infectious Uveitis Treatment
8.4. Middle East & Africa Uveitis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. Online Pharmacies
8.4.1.4. Drug Stores
8.5. Middle East & Africa Uveitis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.2. GCC Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.3. GCC Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
8.5.1.4. GCC Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.5. South Africa Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.6. South Africa Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.7. South Africa Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
8.5.1.8. South Africa Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.9. Egypt Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.10. Egypt Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.11. Egypt Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
8.5.1.12. Egypt Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.13. Nigeria Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.14. Nigeria Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.15. Nigeria Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
8.5.1.16. Nigeria Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Uveitis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Uveitis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Uveitis Treatment Market by Cause, Value (US$ Bn), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Uveitis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Treatment Type vs Disease Type Heatmap
9.2. Manufacturer vs Disease Type Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Panacea Biotec Ltd.
9.5.1.1. Company Overview
9.5.1.2. Treatment Type Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Strides Pharma Science Limited.
9.5.2.1. Company Overview
9.5.2.2. Treatment Type Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Novartis AG
9.5.3.1. Company Overview
9.5.3.2. Treatment Type Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Bausch & Lomb Incorporated.
9.5.4.1. Company Overview
9.5.4.2. Treatment Type Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. ALLERGAN
9.5.5.1. Company Overview
9.5.5.2. Treatment Type Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Santen Pharmaceutical Co., Ltd.
9.5.6.1. Company Overview
9.5.6.2. Treatment Type Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Merck & Co., Inc.
9.5.7.1. Company Overview
9.5.7.2. Treatment Type Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. OphthaliX Inc.
9.5.8.1. Company Overview
9.5.8.2. Treatment Type Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Alimera Sciences Inc.
9.5.9.1. Company Overview
9.5.9.2. Treatment Type Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. AbbVie Inc.
9.5.10.1. Company Overview
9.5.10.2. Treatment Type Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Eyegate Pharmaceuticals; Inc.
9.5.11.1. Company Overview
9.5.11.2. Treatment Type Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Panacea Biotec Ltd.
  • Strides Pharma Science Limited.
  • Novartis AG
  • Bausch & Lomb Incorporated.
  • ALLERGAN
  • Santen Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • OphthaliX Inc.
  • Alimera Sciences Inc.
  • AbbVie Inc.
  • Eyegate Pharmaceuticals; Inc.

Methodology

Loading
LOADING...